How Epstein Barr virus shapes lupus autoimmunity: mechanistic insights and therapeutic perspectives
-
By
-
Rada Miskovic
-
Ivica Jeremic
-
Danijela Miljanovic
-
Andja Cirkovic
-
Ana Banko
-
June 2, 2026
-
Clinical Scorecard: The Role of Epstein-Barr Virus in Modulating Autoimmunity in Lupus: Insights into Mechanisms and Treatment Options
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | EBV infection disturbs immune homeostasis and contributes to the breakdown of self-tolerance through specific pathways. |
| Target Population | |
| Care Setting | |
Key Highlights
- EBV is an active driver of lupus pathogenesis, not merely a passive trigger, due to its role in immune dysregulation.
Guideline-Based Recommendations
Diagnosis
Management
- Consider B-cell targeted therapies such as rituximab or other novel agents to suppress EBV reservoirs.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Individuals diagnosed with systemic lupus erythematosus (SLE)
Focus on therapies that target EBV-infected B cells and disrupt EBV latency.
Clinical Best Practices
- Implement strategies such as antiviral therapy or monitoring protocols to manage EBV reactivation in SLE.
Related Resources & Content
